DAFTAR PUSTAKA

Abdulghani, M. M., Abbas, M. N., & Mohammed, W. R. (2019). Immunohistochemical Expression of Epidermal Growth Factor Receptor in Astrocytic Tumors in Iraqi Patients. *Open Access Macedonian Journal of Medical Sciences*, *7*(21), 3514–3520. https://doi.org/10.3889/oamjms.2019.751

Adam Cohen, M. (2013). IDH1 and IDH2 Mutations in Gliomas. *NIH Public Access*.

Al-Nuaimy WM. P53 expression in glioma: An immunohistochemical study. Jurnal of the Arab Board of Health Spescialization vol.14, No.3, 2013.

Bhalala, N.K., Patel, N.A., Vora, H. (2019). Clinical significance of IDH1, EGFR, p53 and MIB1 in Astrocytoma Patients. http://doi.org/10.37794/IJSRR.2019.8417

Cloughesy, T. F., Cavenee, W. K., & Mischel, P. S. (2014). Glioblastoma: From Molecular Pathology to Targeted Treatment. *Annual Review of Pathology: Mechanisms of Disease*, *9*(1), 1–25. https://doi.org/10.1146/annurev-pathol-011110-130324

EDY, S. (2013). *Clinical Characteristics and Histopathology of Brain Tumor at Two Hospitals in Bandar Lampung*. *69*, 48–56.

Fitiriana, D.F. (2015). Ekspresi Epidermal Growth Factor Receptor (EGFR) dan Ki-67 pada Astrositoma. Majalah Patologi. Vol.24, No.3.

Frosch, M. P., & Anthony, D. C. (2015). Tumors-Gliomas. In V. Kumar & A. K. Abbas (Eds.), *Robbins and Cotran Pathologic Basis of Disease* (9th ed., pp. 1306–1310). Elsevier Inc.

Gargini, R., Segura-Collar, B., & Sánchez-Gómez, P. (2020). Cellular plasticity and tumor microenvironment in gliomas: The struggle to hit a moving target. Cancers, 12(6), 1–24. https://doi.org/10.3390/cancers12061622

Globocan Observatory, W. (2019). Cancer Today - World. *International Agency for Research on Cancer*, *876*, 2018–2019.

Hanif, F., Muzaffar, K., Perveen, K., Malhi, S. M., & Simjee, S. U. (2017). Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. *Asian Pacific Journal of Cancer Prevention*, *18*(1), 3–9. https://doi.org/10.22034/APJCP.2017.18.1.3

Harris, S. L., & Levine, A. J. (2005). The p53 pathway: Positive and negative feedback loops. *Oncogene*, *24*(17), 2899–2908. https://doi.org/10.1038/sj.onc.1208615

Heberland, C. (2007). Tumors of the central nervous system. *Text-Book of Neuro-Oncology*.

Holland, E. C. (2001). Gliomagenesis: Genetic alterations and mouse models. *Nature Reviews Genetics*, *2*(2), 120–129. https://doi.org/10.1038/35052535

Ichimura, K. (2012). Molecular pathogenesis of IDH mutations in gliomas. *Brain Tumor Pathology*, *29*(3), 131–139. https://doi.org/10.1007/s10014-012-0090-4

Issaeva, N. (2019). P53 signaling in cancers. *Cancers*, *11*(3), 14–16. https://doi.org/10.3390/cancers11030332

Kalkan, R. (2015). Glioblastoma stem cells as a new therapeutic target for glioblastoma. *Clinical Medicine Insights: Oncology*, *9*, 95–103. https://doi.org/10.4137/CMO.S30271

Karsy, M., Neil, J. A., Guan, J., Mahan, M. A., Colman, H., & Jensen, R. L. (2015). Erratum to A practical review of prognostic correlations of molecular biomarkers in glioblastoma [Neurosurg Focus 38, 3, E4, (2015)]. *Neurosurgical Focus*, *38*(6), 1–8. https://doi.org/10.3171/2015.4.FOCUS14755a

Khani, P., Nasri, F., Khani Chamani, F., Saeidi, F., Sadri Nahand, J., Tabibkhooei, A., & Mirzaei, H. (2019). Genetic and epigenetic contribution to astrocytic gliomas pathogenesis. *Journal of Neurochemistry*, *148*(2), 188–203. https://doi.org/10.1111/jnc.14616

Kloosterhof, N. K., Bralten, L. B. C., Dubbink, H. J., French, P. J., & van den Bent, M. J. (2011). Isocitrate dehydrogenase-1 mutations: A fundamentally new understanding of diffuse glioma? *The Lancet Oncology*, *12*(1), 83–91. https://doi.org/10.1016/S1470-2045(10)70053-X

Konovalov, N. A., Asyutin, D. S., Shayhaev, E. G., Kaprovoy, S. V., & Timonin, S. Y. (2019). Molecular biomarkers of brain and spinal cord astrocytomas. *Acta Naturae*, *11*(2), 17–27. https://doi.org/10.32607/20758251-2019-11-2-17-27

KPKN. (2017). *Pedoman Nasional Pelayanan Kedokteran-Tumor Otak*.

Kumar, V, A. (2017). *Robbins Basic 10 edition. Philadelphia*. ElsevierCompany.

Lee, K. S., Choe, G., Nam, K. H., Seo, A. N., Yun, S., Kim, K. J., Cho, H. J., & Park, S. H. (2013). Immunohistochemical classification of primary and secondary glioblastomas. *Korean Journal of Pathology*, *47*(6), 541–548. https://doi.org/10.4132/KoreanJPathol.2013.47.6.541

Leece, R., Xu, J., Ostrom, Q. T., Chen, Y., Kruchko, C., & Barnholtz-Sloan, J. S. (2017). Global incidence of malignant brain and other central nervous system tumors by histology, 2003-2007. *Neuro-Oncology*, *19*(11), 1553–1564. https://doi.org/10.1093/neuonc/nox091

Louis, D. (2016). *The 2016 WHO classification of tumors of the central nervous system* (D. Louis & et al Wiestler, Otmar (eds.); 4th ed.). IARC.

Louis, D. N., Deimling, A. von, & Cavenee, W. K. (2016). Diffuse astrocytic and oligodendroglial tumours-Introduction. In D. N. Louis (Ed.), *The 2016 WHO classification of tumors of the central nervous system* (4th ed., Issue 6, pp. 16–17). International Agency for Research on Cancer (IARC).

Louis D, N., M.L, S., & P.C, Burger, et al. (2016). Glioblastoma, IDH-wildtype. In D. N. Louis (Ed.), *WHO Classification of Tumours of the Central Nervous System* (4th ed., pp. 38–45). International Agency for Research on Cancer (IARC).

Loussouarn, D., Le Loupp, A. G., Frenel, J. S., Leclair, F., Von Deimling, A., Aumont, M., Martin, S., Campone, M., & Denis, M. G. (2012). Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. *International Journal of Oncology*, *40*(6), 2058–2062. https://doi.org/10.3892/ijo.2012.1404

Madani Hastutyosunu. (2020). *CLINICAL AND HISTOPATHOLOGICAL CHARACTERISTICS OF PRIMARY*. *9*, 293–300.

Maiiti A, Keya Ghosh, Sami Basu. (2008). Epidermal growth factor receptor and proliferating cell nuclear antigen in astrocytomas. https://doi.org/10.4103/0028-3886.44827

Marta Mellai, Valentina Caldera, L. A. and D. S. (2013). The Distribution and Significance of IDH Mutations in Gliomas. *Intech*, *32*(July), 137–144. http://www.intechopen.com/books/trends-in-telecommunications-technologies/gps-total-electron-content-tec- prediction-at-ionosphere-layer-over-the-equatorial-region%0AInTec%0Ahttp://www.asociatiamhc.ro/wp-content/uploads/2013/11/Guide-to-Hydropower.pdf

Metellus, P., Colin, C., Taieb, D., Guedj, E., Nanni-Metellus, I., De Paula, A. M., Colavolpe, C., Fuentes, S., Dufour, H., Barrie, M., Chinot, O., Ouafik, L., & Figarella-Branger, D. (2011). IDH mutation status impact on in vivo hypoxia biomarkers expression: New insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. Journal of Neuro-Oncology, 105(3), 591–600. https://doi.org/10.1007/s11060-011-0625-2

Montomery RM, Queiroz LS, Rogerio F. (2014). EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation. http://doi.org/10.1590/0004-282X20150059

Nayak, A., Ralte, A. M., Sharma, M. C., Sigh, V. P., Mahapatra, A. K., Mehta, V. S., & Sarkar, C. (2004). P53 Protein Alterations in Adult Astrocytic Tumors and Oligodendrogliomas. *Neurology India*, *52*(2), 228–232.

Nweke M, Ogun G, Adeleye A, Okolo CA, Adesina A. (2020). Immunohistochemical characterisation and histopathology Astrocytic neoplasms at a tertiary Nigerian hospital. https://doi.org/10.1111/ijcp.14094

Omer, N. S., Jalal, J. A., & Ismael, A. T. (2018). *IDH1 (R132H) Immunoexpression in Glioma*. *1*(May 2019). https://doi.org/10.13140/RG.2.2.15064.96005

Rasmussen, B. K., Hansen, S., Laursen, R. J., Kosteljanetz, M., Schultz, H., Nørgård, B. M., Guldberg, R., & Gradel, K. O. (2017). Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I–IV in the the Danish Neuro-Oncology

Registry. *Journal of Neuro-Oncology*, *135*(3), 571–579. https://doi.org/10.1007/s11060-017-2607-5

Sabbah, D. A., Hajjo, R., & Sweidan, K. (2020). Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. *Current Topics in Medicinal Chemistry*, *20*(10), 815–834. https://doi.org/10.2174/1568026620666200303123102

Sarkar, A., & Chiocca, E. A. (2012). Glioblastoma and Malignant Astrocytoma. *Brain Tumors*, 384–407. https://doi.org/10.1016/B978-0-443-06967-3.00021-1

Sipayya, V., Sharma, K.C., Singh, A. (2022). Immunohistochemical expression of IDH1 in gliomas: A tissue microarray-based approach. Cancer Journal. http://doi.org/243.60.251.80. IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance. National Library of Medicine. http://doi.org/10.1309/AJCPZOIY3WY4KIKE

Turkalp, Z., Karamchandani, J., & Das, S. (2014). IDH mutation in glioma: New insights and promises for the future. *JAMA Neurology*, *71*(10), 1319–1325. https://doi.org/10.1001/jamaneurol.2014.1205

Uribe, M. L., Marrocco, I., & Yarden, Y. (2021). EGFR in Cancer: Signalling Mechanisms, Drugs, and Acquired Resistance. *Cancers*, *13*, 2748. https://doi.org/10.11434/kyorinmed.27.596

Van Den Bent, M. J., Dubbink, H. J., Marie, Y., Brandes, A. A., Taphoorn, M. J. B., Wesseling, P., Frenay, M., Tijssen, C. C., Lacombe, D., Idbaih, A., Van Marion, R., Kros, J. M., Dinjens, W. N. M., Gorlia, T., & Sanson, M. (2010). IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. *Clinical Cancer Research*, *16*(5), 1597–1604. https://doi.org/10.1158/1078-0432.CCR-09-2902

Weingart, JD;McGirt, M. (2010). High-Grade Astrocytoma/Glioblastoma. *Neuro-Oncology of CNS Tumors*.

Zhu, J., Zuo, J., Xu, Q., Wang, X., Wang, Z., & Zhou, D. (2011). Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients. *Medical Hypotheses*, *76*(4), 602–603. https://doi.org/10.1016/j.mehy.2011.01.011

LAMPIRAN

Lampiran 1: Tabulasi Data

No.	Sediaan	Nomor RM	Diagnosa	Jenis Kelamin	Umur	Lokasi massa	Status IDH1	Scoring EGFR	Scoring P53
1	HUH.20.488	0	Diffuse Astrocytoma	L	22 thn	Fossa Posterior	Wild	0	<10%
2	P19.865	870754	Diffuse Astrocytoma	P	30 thn	Cerebellum	Wild	+3	<10%
3	P18.4138	835807	Diffuse Astrocytoma	L	16 thn	-	Mutant	0	<10%
4	P17.0452	785755	Diffuse Astrocytoma	L	65 thn	Intracranial	Wild	+3	<10%
5	P18.0642	818601	Diffuse Astrocytoma	L	42 thn	Otak	Mutant	+3	<10%
6	P19.1215	854503	Diffuse Astrocytoma	P	28 thn	Hipofise	Mutant	+1	<10%
7	P17.1046	761288	Diffuse Astrocytoma	L	35 thn	Intrakranial	Wild	+2	<10%
8	P17. 3894	819791	Diffuse Astrocytoma	P	30 thn	Intradura intrameduller	Mutant	0	<10%
9	P17.0872	786694	Diffuse Astrocytoma	P	21 thn	Fossa Posterior	Wild	+2	<10%
10	P17.2171	801439	Diffuse Astrocytoma	L	6 thn	Cerebellum	Mutant	+1	<10%
11	P18.4536	864586	Diffuse Astrocytoma	L	67 thn	Cerebellum	Wild	+2	<10%
12	P20.1763	920853	Diffuse Astrocytoma	L	70 thn	Cerebellum	Wild	+1	<10%
13	P18.2140	782568	Diffuse Astrocytoma	L	5 thn	Cerebellum	Mutant	0	≥10%
14	P19. 4513	899702	Diffuse Astrocytoma	L	32 thn	Frontal Sin	Wild	+3	≥10%
15	P17.2376	806159	Diffuse Astrocytoma	L	36 thn	Temporal	Mutant	+2	<10%
16	P20.251	905611	Diffuse Astrocytoma	P	42 thn	Intrakranial	Mutant	+3	<10%
17	P18.4488	55908	Diffuse Astrocytoma	P	42 thn	Otak	Wild	0	≥10%
18	P15.2365	715182	Diffuse Astrocytoma	P	32 thn	Occipital	Mutant	0	<10%
19	P17.1038	761288	Diffuse Astrocytoma	L	43 thn	Parietal	Mutant	+3	<10%
20	9659	0	Anaplastik astrocytoma	P	43 thn	Cerebellum	Mutant	+1	<10%
21	35585	0	Anaplastik Astrocytoma	L	67 thn	-	Mutant	+3	<10%
22	P18.4374	862774	Anaplastik Astrocytoma	P	57 thn	Temporal	Mutant	+3	≥10%
23	P18.3766	793721	Anaplastik Astrocytoma	L	34 thn	Parietal	Mutant	+3	≥10%
24	P19.1357	874470	Anaplastik Astrocytoma	P	7 thn	Temporoparietal	Mutant	0	<10%

No.	Sediaan	Nomor RM	Diagnosa	Jenis Kelamin	Umur	Lokasi massa	Status IDH1	Scoring EGFR	Scoring P53
25	P18.0785	833072	Anaplastik Astrocytoma	L	20 thn	Otak	Mutant	+3	≥10%
26	P17.2597	808048	Anaplastik Astrocytoma	P	38 thn	Intracerebri	Mutant	+3	≥10%
27	P17.2907	810474	Anaplastik Oligoastocytoma	L	22 thn	Cortex cerebri	Mutant	0	<10%
28	P17.4120	821062	Anaplastik Astrocytoma	P	42 thn	Frontotemporal	Mutant	+3	≥10%
29	P19. 2516	862774	Anaplastik Astrocytoma	P	58 thn	Intracerebri	Wild	+3	≥10%
30	P17.1853	798048	Anaplastik Astrocytoma	L	63 thn	Vertebra L5-S1	Mutant	+1	<10%
31	48444		Anaplastik Astrocytoma	P	42 thn	Parietal	Mutant	+1	<10%
32	834	Siloam	High Grade Astrocytoma	P	50 thn	Intracerebri	Mutant	+3	≥10%
33	P21.1601		Anaplastik Astrocytoma	L	47 thn	Parietal	Mutant	+3	≥10%
34	HUH21.378	813465	Glioblastoma	P	9 thn	Temporoparietal	Mutant	+3	<10%
35	P19.013	867093	Glioblastoma	L	53 thn	Frontotemporal	Mutant	+2	≥10%
36	37536	0	Glioblastoma	L	53 thn	Intracerebri	Mutant	+3	<10%
37	35671	0	Giant Cell Glioblastoma	L	63 thn	-	Mutant	+2	<10%
38	SWG 20.001	43899	Glioblastoma	P	39 thn	Intracerebri	Mutant	+3	≥10%
39	P20.1010	912097	Glioblastoma	L	17 thn	Intrakranial	Mutant	0	<10%
40	SWG.79A	42254	Glioblastoma	L	49 thn	Intracerebri	Mutant	+3	<10%
41	37781	0	Glioblastoma	L	43 thn	-	Mutant	+3	<10%
42	P19.057	86440	Glioblastoma	P	45 thn	Temporoparietal	Wild	0	<10%
43	P17.2882	395203	Glioblastoma	L	70 thn	Intracerebri	Mutant	+3	<10%
44	P17.4517	798997	GB Adenoid	L	26 thn	tumor otak	Wild	+2	<10%
45	P17.2943	785755	Glioblastoma	L	65 thn	tumor otak	Mutant	+3	≥10%
46	P16.2098	709176	Glioblastoma	L	39 thn	Frontal	Wild	+2	≥10%
47	P18.3275	853727	Glioblastoma	P	48 thn	Otak	Wild	+1	≥10%
48	P19. 1376	878458	Glioblastoma	L	62 thn	Intracerebri	Mutant	+1	<10%
49	P17.4390	822320	Glioblastoma	P	20 thn	Intracerebri	Wild	0	≥10%
50	P17.1972	795785	Glioblastoma	L	46 thn	Hemisfer	Mutant	+3	<10%
51	P17.3595	813678	Glioblastoma	L	29 thn	Otak	Wild	+2	<10%
52	P17.4114	802972	Glioblastoma	L	7 thn	Intracranial	Wild	+3	<10%
53	P17.4467	579139	Glioblastoma	L	37 thn	Intracranial	Mutant	+2	<10%
54	19. 2056	Siloam	Giant Cell Glioblastoma	L	58 thn	-	Mutant	+3	≥10%
55	P15. 2931	635065	Glioblastoma	L	14 thn	Frontal	Mutant	+2	≥10%
56	19. 2416	Siloam	Glioblastoma	L	62 thn	Occipital	Mutant	+3	<10%
57	P19. 609	872486	Glioblastoma	P	8 thn	Intracerebri	Mutant	+2	≥10%

No.	Sediaan	Nomor RM	Diagnosa	Jenis Kelamin	Umur	Lokasi massa	Status IDH1	Scoring EGFR	Scoring P53
58	P21. 690	62629	Glioblastoma	L	52 thn	Parieto-occipital	Wild	+3	<10%
59	17. 1222	Siloam	Glioblastoma	P	37 thn	-	Mutant	+3	≥10%
60	HUH21.298		Giant Cell Glioblastoma	L	29 thn	Parietal	Mutant	+3	≥10%
61	HUH21.303		Giant Cell Glioblastoma	L	21 thn	Temporal	Mutant	+3	≥10%
62	49177	sdpm	Glioblastoma	P	49 thn	Frontal	Mutant	+3	<10%
63	P21.1099	934138	Glioblastoma	P	59 thn	Frontoparietal	Mutant	+3	<10%
64	P21.2454	943644	Anaplastik Astrocytoma	P	27 thn	Frontal dextra	Mutant	+3	<10%
65	P22.0319	962807	Glioblastoma	L	32 thn	-	Wild	+2	<10%
66	P22.391	961382	Anaplastik Astrocytoma	L	50 thn	Cerebellum	Mutant	+2	<10%
67	P22.0611	964704	Glioblastoma	L	52 thn	-	Mutant	+3	≥10%
68	P22.1195	966336	Diffuse Astrocytoma	P	40 thn	Intracerebri	Wild	+1	<10%
69	P22.1539	975248	Giant Cell Glioblastoma	P	17 thn	-	Mutant	+3	≥10%

Lampiran 2. Persetujuan Etik



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari..MMed.PhD. SpGK TELP. 081241850858. 0411 5780103. Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 476/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 1 September 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22070383	No Sponsor Protokol	
Peneliti Utama	**dr. Nurul Fardillah**	Sponsor	
Judul Peneliti	PERBANDINGAN EKSPRESI PROTEIN EGFR DAN P53 PADA ASTROCYTOMA IDH-MUTANT DAN IDH-WILDTYPE		
No Versi Protokol	**2**	Tanggal Versi	**31 Agustus 2022**
No Versi PSP		Tanggal Versi	
Tempat Penelitian	Laboratorium PA RS Universitas Hasanuddin Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku **1 September 2022** sampai **1 September 2023**	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan